The Science of Longevity Research: What We Know in 2026
August 2, 2026 · Frisian News
Longevity startups raised $4.7 billion in 2024 and 2025, yet human lifespan has not increased since the 1990s. Most breakthroughs in mice do not apply to humans, while the billionaire-funded field chases revolutionary claims instead of proven interventions.
Longevity startups raised large sums in 2024 and 2025. Life expectancy growth in developed nations has slowed. The gap between investment and outcome is growing wider.
The money flows from predictable sources: Bezos, Sam Altman, Peter Thiel. Venture capitalists follow. The narrative is seductive. One company, Altos Labs, raised $3 billion on the theory that reprogramming cells could reverse aging. Another, Calico, has spent heavily since 2013 with no approved drug on the market. Yet the hype machine drums on, undeterred by results.
The science itself is more modest. Most findings in mice do not replicate in humans. Caloric restriction extends lifespan in rodents but shows no clear human benefit across large studies. Rapamycin, a drug tested in primates, showed a modest lifespan extension in mice, not humans. Metformin, a diabetes drug, correlates with slightly longer life in some studies, but causation remains unclear. The best-supported interventions are unglamorous: regular exercise, eight hours of sleep, not smoking, maintaining social ties.
Billionaire interest in aging research is not charitable curiosity. These men want to escape death. That focus shapes the entire field. Venture money chases longevity claims that sound revolutionary, not interventions that are free or cheap. A study showing that walking for 30 minutes daily reduces mortality does not attract $100 million in funding. A startup promising cellular immortality does.
Epidemiologists do the honest work in longevity research, tracking millions of people. Labs chase cellular immortality instead. But that work pays no venture returns and makes no billionaire rich. So it remains underfunded and under-hyped. The field's actual progress is real but slow. The investment landscape, however, remains divorced from reality.
Published August 2, 2026 · Frisian News